Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04186221 · ClinicalTrials.gov registry record · NA

OCS Liver PROTECT Continued Access Protocol

A NA study of Liver Transplant, sponsored by TransMedics.

Completed
Registry status
NA
Development phase
74
Enrollment target
17
Study locations

NCT04186221 is a NA study of Liver Transplant that has completed, run by TransMedics. The registered enrollment target is 74 participants, below the 5,454-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04186221, a NA study of Liver Transplant, has completed, sponsored by TransMedics.

COMPLETED
Registry status
NA
Development phase
74 participants
Enrollment target
17
Study locations

Study Summary

Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers.

Conditions Studied

Interventions

  • DEVICE OCS Liver System

Study Locations (17)

California

  • Scripps - La Jolla
  • University of California San Diego - La Jolla
  • UCSF - San Francisco

Texas

  • University of Texas Southwest - Dallas
  • Houston Methodist Hospital - Houston
  • The University of Texas Health Science Center at San Antonio - San Antonio

New York

  • Mount Sinai Hospital - New York
  • Montefiore Einstein Center for Transplantation - The Bronx

Virginia

  • University of Virginia - Charlottesville
  • Virginia Commonwealth University Health System - Richmond

Florida

  • Tampa General - Tampa

Maryland

  • Johns Hopkins - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • Henry Ford Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2020-02-03
Est. Completion 2023-02-02
Phase NA

Sponsor

TransMedics

23 total trials

What the Registry Record Tells You About NCT04186221

The ClinicalTrials.gov registry entry for NCT04186221 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,454-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower). The listed sponsor is TransMedics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 1 intervention - of which OCS Liver System is the first listed.

NCT04186221 reports 17 study locations spanning 11 distinct geographic areas - top geographies include California, Texas, New York.

Frequently Asked Questions

What is clinical trial NCT04186221 about?

NCT04186221 is a clinical study titled "OCS Liver PROTECT Continued Access Protocol". Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers.

What is the current status of trial NCT04186221?

This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2020-02-03. Estimated completion is 2023-02-02.

What conditions does trial NCT04186221 study?

This clinical trial studies the following conditions: Liver Transplant.

What interventions are being tested in trial NCT04186221?

The interventions under investigation include: OCS Liver System (DEVICE).

Who is sponsoring clinical trial NCT04186221?

This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04186221 being conducted?

This trial has 17 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.